CAYA Cancer Retrospective Cohort Study
Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Young Adult Cancer
- Adolescent Cancer
- Childhood Cancers
- Acute Lymphoblastic Leukemia (ALL)
- Lymphoblastic Lymphoma (LBL)
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Resonance, Inc.
- Enrolment target
- 18,000
- Started
- 4 June 2025
- Main results due
- 4 June 2028
- Study sites
- 7
- Registry updated
- 29 September 2026
Can you take part?
- Ages 0 years to 21 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria:
Subjects must meet all the following criteria to be included in this registry:
1. Participants must be willing and able to provide informed consent prior to enrollment in the registry.
1. For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian.
2. Note: Exemption applies to this criterion when waiver of informed consent/assent is granted by Institutional Review Board(IRB)/Independent Ethics Committee(IEC)/Competent Authorities(CAs).
2. A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date.
3. Age 0 to 21 years at the time of diagnosis.
4. Received substantial anti-cancer treatment at the participating center, including but not limited to:
1. Chemotherapy
2. Surgery
3. Radiation therapy
4. Immunotherapy
5. Medical records are available and accessible for review
Exclusion Criteria:
* Subjects meeting any of the following criteria will be excluded from this registry:
1. Patients who only visited the participating center for:
1. Consultation without subsequent primary anti-cancer treatment at the participating center
2. Pathology, radiology, or other diagnostic evaluations without treatmentWhat this study is about
In the sponsor’s own words, from the registry.
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.
Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare.
This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.
Study sites(7)
Yeolyan Center for Cancer and Blood Disorders
Yerevan, Armenia
Recruiting
The Children's Cancer Hospital Egypt 57357
Cairo, Egypt
Not yet recruiting
Fundación Ayúdame a Vivir
El Salvador, El Salvador, El Salvador
Recruiting
Unidad Nacional de Oncología Pediátrica (UNOP)
Guatemala City, Guatemala
Recruiting
Hospital Mario Catarino Rivas
San Pedro Sula, Cortés Department, Honduras
Recruiting
Hospital Escuela
Tegucigalpa, Distrito Central, Honduras
Recruiting
Kilimanjaro Christian Medical Center
Moshi, Tanzania
Not yet recruiting
Showing 7 of 7 sites. 5 of the 7 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07246213. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me